In loving memory of Colleen Sigman

On August 6, 2007, Colleen Sigman passed away from renal cell carcinoma. Colleen Sigman is not just another statistic for kidney cancer she was a daughter, a wife, a mother, a grandma (maw maw), a niece, an Aunt, a sister-in-law, and a cousin and most of all she was my best friend and my life along with many others will never be the same without her. A few months before her death we found out that there were not many options out there for a patient with renal cell carcinoma. In this day and age you would think that we would be further along in all types of cancer than we really are today. We were shocked by the cost of medication. A 30 day supply of medication for nausea was 1,500 dollars. One pill for chemotherapy was 2,500. Those are just two examples the cost just starts to add up and can become overwhelming for everyone involved. I decided after several months of crying and not leaving my house that I needed to find a way to keep my mom's memory alive. I want to be able to help families that are dealing with the same thing that my family dealt with. I want to be able to help families pay for the medications that they need, and provide support for the patient as well as the family. These things I can not do alone. That is why I created a website in memory of my mom. The website is set up for anyone to share their story and find support. I also need the help from people willing to donate. 100% of all donations will be donated to the Kidney Cancer Association.  The Kid...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

We report a case of ureteral stump carcinoma following a radical nephrectomy for renal cell carcinoma. A 76-year-old man was diagnosed as having ascending colon cancer and a right renal carcinoma. He was treated with partial colon resection and radical nephrectomy without lymphadenectomy. The histology was renal cell carcinoma. Three years after that surgery, he complained of intermittent macrohematuria. Abdominal computed tomography (CT) suggested a solid mass in the pelvis. We then performed a biopsy with CT guidance. An epithelial tumor was suspected by immunohistochemistry. A total excision of ureter was then performed...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
AbstractPancreatectomy might confer a survival benefit in patients with metastatic tumors of the pancreas (MTPs); however, the optimal treatment for MTP has not been established. We reviewed six patients with MTP undergoing pancreatectomy and discussed the clinical features, surgical treatment, and survival. The sites of primary cancer included renal cell carcinoma (RCC) (n = 5; 83.3%) and rectal cancer (n = 1; 16.7%). The median interval between the resection of the primary site and the development of MTP was 157 months (range, 16–180 months). Three (60.0%) of the five cases of ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewInterleukin-10 (IL-10) is a cytokine with anti-inflammatory properties, which induces activation and proliferation of antigen-activated intratumoral CD8+ T cells. This review discusses the evolution of pegylated IL-10 (pegilodecakin) from preclinical investigation through first-in-human studies in oncology.Recent FindingsPegilodecakin was evaluated across multiple advanced solid tumors in a large phase 1/1b trial alone and in combination with chemotherapy or anti-PD-1 antibodies. Pegilodecakin monotherapy had immunologic and clinical activity in renal cell carcinoma (RCC) and uveal melanoma. In com...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
CONCLUSION: Anti-PD1 therapy has great potential. Early recognition of the onset of unusual collateral effects is important to improve decision making regarding the treatment of patients with tumors. PMID: 30779841 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
CONCLUSIONS: It follows that the antiangiogenic activity of bevacizumab may be due to a direct effect on angiogenic cytokines released by tumor cells and an indirect effect on the release of pro-angiogenic factors by inflammatory stromal cells. PMID: 30738745 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Abstract Renal cell carcinomas are a group of most common renal malignancies whose clinical intervention is complicated by the lack of early diagnosis and reliable prognosis biomarkers, insensitive radiotherapy and chemotherapy and expensive molecular-targeted drugs. Transcriptional coactivator TAZ has been implicated in the formation and development of various malignancies. However, the biological characteristics and function of TAZ in renal cell carcinoma are still unclear. We attempted to evaluate the potential of TAZ as a promising diagnostic and prognostic molecular marker for renal cell carcinoma. In our stu...
Source: Experimental Cell Research - Category: Cytology Authors: Tags: Exp Cell Res Source Type: research
AbstractImmunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the bi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
CONCLUSIONS: Chemotherapy and inpatient hospital care offer the most potential to reduce spending within OCM-defined episodes. Other sources of savings differ by type of cancer. Assuming patient outcomes are not compromised, low-spending HRRs may be models for lowering cost in cancer care. PMID: 30586495 [PubMed - in process]
Source: The American Journal of Managed Care - Category: Health Management Authors: Tags: Am J Manag Care Source Type: research
Irem Bilgetekin, Mustafa Karaca, Ipek Işık Gönül, Aytuğ Üner, Hayriye Şahinli, Hacer Demir, Aydin Aytekin, Aydin Çiltaû, Mustafa BenekliJournal of Cancer Research and Therapeutics 2018 14(6):1422-1424 Ewing's family of tumors is aggressive tumors and frequently arises from bone and soft tissue. They might also arise from nonosseous structures such as gastrointestinal tract, adrenal glands, or kidney. Primary renal Ewing's sarcoma (ES)/primitive neuroectodermal tumor is an extremely rare entity which has aggressive clinical course. These high-grade malignant tumors predo...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
ConclusionLymphopenia may be an early indicator of irAEs and should be investigated further in prospective trials.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | Heart | Kidney Cancer | Men | Renal Cell Carcinoma | Statistics | Urology & Nephrology | Websites